Currently recruiting for our Phase 2/b clinical trial.

If you’re interested in participating or would like more information, please click here.

Derzeit rekrutieren wir für unsere klinische Phase 2/b-Studie.

Wenn Sie an einer Teilnahme interessiert sind oder weitere Informationen wünschen, klicken Sie bitte hier.

Our Mission

Mission:

Produce safety and efficacy data for our lead therapeutic that warrants approval.

ADvantage Therapeutics is developing therapies to treat neurodegenerative conditions with a major focus on Alzheimer’s Disease (AD). We are currently preparing for clinical trials in Europe and in the US. Furthermore, ADvantage is developing potentially paradigm-changing therapies to treat AD in its labs at the Vienna BioCenter.

MORE ABOUT US Our Breakthrough
Previous Next

“One sometimes finds
what one is not looking for”

By serendipity, a potentially disease-modifying compound for Alzheimer's Disease was discovered.

Over the last 20 years, Alzheimer’s research concentrated on therapies to produce antibodies against different amyloid-beta peptide species, which were shown to accumulate in the brains of Alzheimer’s patients. However, clinical trial efficacy proved elusive.

“The power of Science”

Meanwhile, the research team led by Drs. Frank Mattner, Walter Schmidt and Achim Schneeberger developed a (mimotope-based) vaccine, AD02, against amyloid-beta peptides (with a free N-terminus).

In 2014, the team orchestrated a double-blinded, randomized clinical phase 2 trial with AD02 in 332 Alzheimer’s patients. In this trial, Alhydrogel® (now called AD04™) served as a control group.

“ADvantage Therapeutics is born to achieve the mission”

Unexpectedly, the patients from the control group significantly benefited from the AD04™ application while the AD02 vaccinated groups did not. The shrinkage of the Hippocampus, where memory and orientation are located, was positively impacted by AD04™ treatment coupled with slowdown of cognitive decline.

After several years of negotiation, Frank and Walter bought the patent rights for AD04™. They joined Agustin Fernandez and Jeffrey Madden and founded ADvantage Therapeutics Inc. in order to provide Alzheimer’s patients a transformative, life-enhancing treatment.

Our Science

Summary of Phase 2:
AD04™, a Unique Compound
with Disease Modifying Activity

Large Group of AD Patients Diagnosed According to Biomarker Enhanced Criteria (Phase 2 Clinical Study)

The 2mg IMM-AD04™ control arm of the trial showed a statistically significant slower decline over the combined 4 other groups on clinical outcomes (Cognition and Quality of life) and MRI hippocampal volume as biomarker.

*1 The Hippocampus is the part of the brain that harbors memory and orientation functions.

OUR SCIENCE

Our product candidate, AD04™, is a known immuno-stimulant: this compound has been widely used as an adjuvant in human and animal vaccination programs and has a well-established safety record. However, injection of this compound as single ingredient for the treatment of AD is a proprietary approach.

What results have you seen that support the clinical development of AD04™?

Our data obtained in patients with early AD indicated that AD04™, applied repeatedly to the subcutis of the upper arm induced a statistically significant slower decline over the combined 4 other groups on clinical outcomes (e.g. cognition and quality of life) and MRI hippocampal volume as biomarker. Importantly, reduced loss of the hippocampal volume correlated with significantly less decline in cognitive measures, e.g., adapted Alzheimer’s Disease Assessment Scale-cognitive (aADAS-cog), but not in functional endpoints supporting AD04™ as a therapeutic entity (see “Summary of Phase 2”).

AD04™ tested in the respective clinical trial arm (n=51 patients) was safe and well tolerated. There was neither evidence for autoimmunity nor for hematological abnormalities or hepato-/nephrotoxicity.

MORE ABOUT OUR SCIENCE Our Pipeline

OUR PIPELINE

Our clinical developments and accomplishments leading to a
consistent success.

The world desperately needs disease-modifying therapies for AD: we combine immunology and neuroscience to create first-in-class therapeutics.

MORE ABOUT OUR PIPELINE

OUR TEAM

We will sustain a knowledge-building culture that combines leading-edge scientific skill, unencumbered by conventional assumptions, with a passion for bringing paradigm-changing medical treatments to patients worldwide.

Executive Management
Jeffrey B. Madden

Jeffrey B. Madden

Chief Executive Officer

David Buchsbaum

David Buchsbaum

Chief Financial Officer

Olivier Jarry

Olivier Jarry

Chief Operating Officer

Achim Schneeberger, M.D.

Achim Schneeberger, M.D.

Chief Medical Officer

Walter Schmidt, Ph.D.

Walter Schmidt, Ph.D.

Director, mRNA Division

Carmela Abraham, Ph.D.

Carmela Abraham, Ph.D.

Chief Science Officer

Thomas Hoffmann, Ph.D.

Thomas Hoffmann, Ph.D.

Chief Technology Officer

Scientific Advisory Board
Makoto Kuro-o, M.D., Ph.D.

Makoto Kuro-o, M.D., Ph.D.

Cynthia A. Lemere, Ph.D.

Cynthia A. Lemere, Ph.D.

Rudolph Tanzi, Ph.D.

Rudolph Tanzi, Ph.D.

SAB Chair

Clinical Advisory Board
Serge Gauthier, M.D.

Serge Gauthier, M.D.

Bruno Dubois, M.D.

Bruno Dubois, M.D.

Oliver Peters, M.D.

Oliver Peters, M.D.

COMPANY NEWS

“Time Saved” Calculations to Improve Decision-Making in Progressive Disease Studies

Disease modifying therapies (DMTs) are a focus of research for Alzheimer’s disease (AD). DMTs are expected to change the trajectory of disease progression and slow...

Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics

Dr. Kuro-o to speak at Second Annual Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton, Florida   BOCA RATON, FL and Vienna, Austria, February...

ADvantage Therapeutics Has Commenced Enrollment for Its Phase 2b Clinical Trial of AD04™ for Treatment of Alzheimer’s Disease

MIAMI, November 27, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions by addressing the biology...

ADvantage Therapeutics Welcomes Esteemed Expert in Alzheimer’s Disease and Klotho Protein, Carmela Abraham, Ph.D. as Chief Science Officer

ADvantage also acquires intellectual property to enhance its Alzheimer’s disease and longevity portfolios

ADvantage’s CEO, Jeffrey Madden speaks to Dave, The CareGiver’s Caregiver/Avoiding Burnout

Jeffrey Madden speaks with Dave, The CareGiver's Caregiver to discuss all things Alzheimer's including breakthroughs in research; immunotherapy; pathophysiology; combining with other medications; clinical trial...

ADvantage Therapeutics Secures Approvals for Clinical Trial of AD04™ in Alzheimer’s Disease Treatment in Poland, Bulgaria, and Slovakia

MIAMI, June 20, 2023 (GLOBE NEWSWIRE) -- ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), a pioneer in developing therapies for neurodegenerative conditions with a focus on Alzheimer’s disease, today announced that regulatory authorities in Poland, Bulgaria, and Slovakia have approved its Clinical Trial Application

We are excited about the recent MHRA announcement regarding new regulatory recognition pathways that will facilitate the introduction of innovative drugs to the UK by leveraging other countries' drug registrations.

ADvantage Therapeutics taking disruptive approach to mild Alzheimer’s

Closely-held ADvantage Therapeutics is awaiting regulatory approval in Europe to proceed with a Phase 2b confirmatory clinical trial of its lead drug candidate, AD04, for...

MHRA Grants ADvantage Therapeutics Innovative Licensing and Access Pathway (ILAP) Designation for Novel Lead Product AD04™ for Phase 2b Trial in Alzheimer’s Disease

ILAP Designation accelerates patient access and commercialization   MIAMI, APRIL XX, 2023 (GLOBE NEWSWIRE) – ADvantage Therapeutics, Inc. (“ADvantage” or “the Company”), which is developing...

Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech Conference Held in Boca Raton

Renowned Public Health Advisor Jim O’Neill Joins Board of Directors of ADvantage Therapeutics Appointment announced today at inaugural Entrepreneurship, Longevity and Biotech ConferenceHeld in Boca...

Get the latest updates

Join our mailing list for news updates.

Our Partners